This trial will evaluate the safety and effectiveness of the MitraClip device for the treatment of moderate-to-severe or severe mitral valve leak, also called functional mitral regurgitation, in patients with heart failure.
Learn how the trial will determine safety and effectiveness >
This study will evaluate the Pathological Complete Response, which refers to complete disappearance of a tumor from the breast, when trastuzumab emtansine (TDM-1), lapatinib and Abraxane® are combined. This study is for patients with newly diagnosed HER2 positive breast cancer.
Learn more about assessing the toxicity, safety and efficacy of the drug combination >